Document is current

Article History

Received: 14 May 2025

Accepted: 4 December 2025

First Online: 14 January 2026

Declarations

:

: C.G. Bunick has served as an investigator for AbbVie, Almirall, Apogee, Daiichi Sankyo, LEO Pharma, Ortho Dermatologics, Sun Pharma, Timber, and Palvella; a consultant for AbbVie, Almirall, Apogee, Arcutis, Connect BioPharma, Eli Lilly, EPI Health/Novan, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Sanofi-Regeneron, Takeda, and UCB; and a speaker for and received honoraria from Allergan, Almirall, LEO Pharma, and UCB. N. Magnolo has received honoraria for participation on advisory boards, as a speaker and/or for consultancy from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB Pharma. A. Moore has received honoraria or research funds from Abbvie, Aclaris, Acrotech, Arcutis, Bayer, Bristol Myers Squibb, Cara, Eli Lilly, Galderma, Genentech Roche, Incyte, Janssen, Novartis, Pfizer, Rapt, Regeneron, Roche, and Sanofi. M. Abe has been an investigator, consultant and/or speaker for AbbVie, Amgen, UCB, Eli Lilly, Janssen, LEO Pharma, Novartis, Sanofi, Bristol Myers Squibb, Kyowa-Kirin, Sun Pharma, Maruho and Torii. X. Gao has served as speaker for Eli Lilly, GSK, Janssen, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals Inc., and Sanofi, consultancy/advisory board member for AbbVie, Boehringer Ingelheim, Novartis, Pfizer, Sanofi – investigator; AbbVie, AstraZeneca, BMS, Eli Lilly, Huarun, JiaLan, LEO Pharma, Pfizer, Puqi and Sanofi. C. Lynde has acted as a principal investigator, speaker and/or consultant for AbbVie, Amgen AnatpysBio, Avillon, Arcutis, Bristol-Myers Squibb, Celgene Cipher Genentech, GlenMark, Incyte, Janssen, Leo Pharma, Kyowa, Pfizer, and Merck. N. Ibrahim, G. Levy, B.M. Calimlim, X. Wu, Y. Armendariz, and A. Grada are full-time employees of AbbVie Inc and may hold AbbVie stock and/or stock options. K. Eyerich has received grants and personal fees from AbbVie; has received personal fees from Almirall, Bristol Myers Squibb, LEO Pharma, Lilly, Janssen, Novartis, UCB, and Sanofi; and has received grants from Lilly, LEO Pharma, Janssen, Novartis, and UCB.

: All authors were involved in the interpretation of the data, preparation, and critical review of the manuscript, and approved the final version of the manuscript.

: This study was performed in accordance with the Declaration of Helsinki 1964 and its later amendments. Independent ethics committees or institutional review boards approved the study protocol, informed consent form(s), and recruitment materials before patient enrollment.

: The patients in this manuscript have given written informed consent to publication of their case details.

: Patients provided written informed consent before screening.

: Not applicable

: AbbVie is committed to responsible data sharing regarding the trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (e.g., protocols, clinical study reports, or analysis plans), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for trial data for unlicensed products and indications. These trial data can be requested by any qualified researchers who engage in rigorous, independent, scientific research, and will be provided following review and approval of a research proposal, Statistical Analysis Plan (SAP), and execution of a Data Sharing Agreement (DSA). Data requests can be submitted at any time after approval in the USA and Europe and after acceptance of this manuscript for publication. The data will be accessible for 12 months, with possible extensions considered.